Last10K.com

Altimmune, Inc. (ALT) SEC Filing 10-K Annual Report for the fiscal year ending Friday, December 31, 2021

Altimmune, Inc.

CIK: 1326190 Ticker: ALT

Logo, company name

Description automatically generated

Exhibit 99.1

Altimmune Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update

Data readouts from multiple clinical trials expected during the next 6 to 12 months

Strong cash position of $190.3 million as of December 31, 2021

GAITHERSBURG, MD, -- March 15, 2022

-- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the fourth quarter and full year ended December 31, 2021 and provided a corporate update.

“We expect the next 12 months to be a period of intense execution with value-creating data readouts from multiple clinical trials. We are extremely pleased with the progress of our pemvidutide (ALT-801) program as we showed double-digit weight loss after 12 weeks of treatment, good tolerability without the use of dose titration, and pronounced decreases in serum lipids commonly associated with cardiovascular disease. We also observed a remarkable reduction in liver fat content to undetectable levels after only 6 weeks of pemvidutide treatment in subjects with hepatic steatosis, or fatty liver,” said Vipin K. Garg, Ph.D., President and Chief Executive Officer at Altimmune. “In addition to our ongoing 12-week Phase 1b NAFLD trial, we expect to initiate a 48-week Phase 2 trial of pemvidutide in obesity, the MOMENTUM trial, in the next few weeks and look forward to sharing data from both of these trials later this year. In addition, we expect to read out our HepTcell trial in the first half of 2023.”

Recent Highlights and Anticipated Milestones:

Pemvidutide1 (ALT-801)

Enrollment in Phase 1b nonalcoholic fatty liver disease (NAFLD) trial is over 90% complete, and data readout is expected in Q3 2022

oThe 12-week trial is being conducted at 15 sites in the U.S., with Dr. Stephen A. Harrison serving as Principal Investigator. The trial will be comprised of 72 non-diabetic and diabetic subjects across four treatment arms (pemvidutide 1.2, 1.8, 2.4 mg and placebo).
oThe primary efficacy readouts of this trial are liver fat reduction and weight loss.
oA 52-week biopsy driven Phase 2 non-alcoholic steatohepatitis (NASH) trial is expected to follow the conclusion of the NAFLD trial.

Received U.S. Food and Drug Administration (FDA) clearance of pemvidutide investigational new drug application (IND) for obesity – Initiation of the Phase 2 MOMENTUM trial of pemvidutide in obesity expected in the first quarter of 2022

oThe trial is expected to enroll approximately 320 non-diabetic subjects with either obesity or overweight with at least one obesity-related complication. Subjects will be randomized

1 proposed INN


The following information was filed by Altimmune, Inc. (ALT) on Tuesday, March 15, 2022 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Altimmune, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Altimmune, Inc..

Continue

Assess how Altimmune, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Altimmune, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Rating

Learn More
Bullish Bearish Neutral
Filter Sentiment:
All
Positive
Negative
Filter Category:
All
Financial
Revenue
M & A
Other
Filter Subcategory:
All
Expense
Geography
Product
Shares
Other
Inside Altimmune, Inc.'s 10-K Annual Report:

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Consolidated Balance Sheets
Consolidated Balance Sheets (Parenthetical)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Changes In Stockholders' Equity
Consolidated Statements Of Operations And Comprehensive Loss
Accrued Expenses And Other Current Liabilities
Accrued Expenses And Other Current Liabilities (Tables)
Accrued Expenses And Other Current Liabilities - Schedule Of Accrued Expense And Other Current Liabilities (Detail)
Commitments And Contingencies
Commitments And Contingencies - Additional Information (Details)
Common Stock
Common Stock - Additional Information (Detail)
Contingent Consideration
Contingent Consideration (Tables)
Contingent Consideration - Additional Information (Detail)
Contingent Consideration - Summary Of Fair Value Of Contingent Consideration (Detail)
Employee Benefit Plans
Employee Benefit Plans - Additional Information (Detail)
Fair Value Measurement (Tables)
Fair Value Measurement - Summary Of Assumptions Used To Estimate Fair Value Of Contingent Payments (Detail)
Fair Value Measurements
Fair Value Measurements - Additional Information (Detail)
Fair Value Measurements - Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis (Detail)
Fair Value Measurements - Schedule Of Short Term Investments (Detail)
Income Taxes
Income Taxes (Tables)
Income Taxes - Additional Information (Detail)
Income Taxes - Components Of Deferred Tax Assets And Liabilities (Detail)
Income Taxes - Components Of Income Tax Benefits (Detail)
Income Taxes - Components Of Net Loss Before Income Tax Benefit (Detail)
Income Taxes - Reconciliation Applying Federal Statutory Rate And Effective Income Tax Rate Used To Calculate Income Tax Benefit (Detail)
Income Taxes - Reconciliation Of Unrecognized Tax Benefits (Detail)
Intangible Assets
Intangible Assets (Tables)
Intangible Assets - Additional Information (Detail)
Intangible Assets - Schedule Of Intangible Assets (Detail)
Leases
Leases (Tables)
Leases - Additional Information (Detail)
Leases - Summary Of Maturities Of Lease Liabilities (Detail)
Leases - Summary Of Supplemental Other Information Related To Operating Leases Balance Sheet (Detail)
Nature Of Business And Organization
Net Loss Per Share
Net Loss Per Share (Tables)
Net Loss Per Share - Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share (Detail)
Notes Payable And Other Liabilities
Notes Payable And Other Liabilities (Tables)
Notes Payable And Other Liabilities - Additional Information (Detail)
Notes Payable And Other Liabilities - Summary Of Long-Term Portion Of Outstanding Notes Payable As Well As Other Long-Term Liabilities (Detail)
Property And Equipment, Net
Property And Equipment, Net (Tables)
Property And Equipment, Net - Additional Information (Detail)
Property And Equipment, Net - Summary Of Property And Equipment, Net (Detail)
Stock-Based Compensation
Stock-Based Compensation (Tables)
Stock-Based Compensation - Additional Information (Detail)
Stock-Based Compensation - Schedule Of Information Related To Stock Options Outstanding (Detail)
Stock-Based Compensation - Schedule Of Stock-Based Compensation Expense (Detail)
Stock-Based Compensation - Summary Of Fair Value Of Stock Options Issued To Employees (Detail)
Stock-Based Compensation - Summary Of Restricted Stock Activity (Detail)
Subsequent Events
Subsequent Events (Details)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Policies)
Summary Of Significant Accounting Policies (Tables)
Summary Of Significant Accounting Policies - Additional Information (Detail)
Summary Of Significant Accounting Policies - Summary Of Depreciation And Amortization Recorded Using Straight-Line Method Over Estimated Useful Lives (Detail)
U.S. Government Contracts And Grants
U.S. Government Contracts And Grants - Additional Information (Detail)
Warrants
Warrants (Tables)
Warrants - Additional Information (Detail)
Warrants - Summary Of Common Stock Warrants Outstanding (Detail)
Warrants - Summary Of Warrant Activity (Detail)
Ticker: ALT
CIK: 1326190
Form Type: 10-K Annual Report
Accession Number: 0001558370-22-003659
Submitted to the SEC: Tue Mar 15 2022 4:06:20 PM EST
Accepted by the SEC: Tue Mar 15 2022
Period: Friday, December 31, 2021
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/alt/0001558370-22-003659.htm